Huijberts, Sanne C. F. A.
van Geel, Robin M. J. M.
van Brummelen, Emilie M. J.
Opdam, Frans L.
Marchetti, Serena
Steeghs, Neeltje
Pulleman, Saskia
Thijssen, Bas
Rosing, Hilde
Monkhorst, Kim
Huitema, Alwin D. R.
Beijnen, Jos H.
Bernards, René
Schellens, Jan H. M.
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 9 December 2019
Accepted: 24 March 2020
First Online: 9 April 2020
Compliance with ethical standards
:
: JB and JS (partly) hold a patent on oral taxane formulations, and are shareholders and part-time employees of Modra Pharmaceuticals, a spin out company developing oral taxanes; not related to the manuscript. RB holds a patent on the use of MEK and HER inhibitors in <i>KRAS</i>-mutant cancers. The other authors declare that they do not have a conflict of interest related to this manuscript.